Table 1 List of AD and CON cases used for this study
From: Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology
Cases used for Western blotting | |||||||
A. Hippocampus | |||||||
Case number | Braak stage (NFT) | Phase of Aβ deposits | CERAD neuritic plaque score | Sex | Age | PMD | Pathological diagnosis |
1 | 0 | O | 0 | M | 51 | 7.45 | CON |
2 | 1 | B | 0 | M | 85 | 7.05 | CON |
3 | 1 | A | 0 | F | 60 | 7.30 | CON |
4 | 2 | O | 0 | F | 81 | 5.30 | CON |
5 | 3 | A | 0 | F | 91 | 5.20 | CON |
6 | 4 | C | 2 | F | 91 | 6.05 | AD |
7 | 5 | C | 2 | F | 89 | 4.40 | AD |
8 | 5 | C | 2 | M | 81 | NA | AD |
9 | 5 | B | 2 | F | 69 | 7.10 | AD |
10 | 6 | C | 3 | F | 69 | 5.30 | AD |
11 | 6 | C | 3 | F | 68 | 3.50 | AD |
12 | 6 | C | 3 | F | 67 | 5.50 | AD |
B. Temporal cortex | |||||||
13 | 0 | B | 0 | M | 74 | 7.45 | CON |
14 | 0 | O | 0 | M | 66 | 7.45 | CON |
15 | 1 | O | 0 | M | 77 | 8.25 | CON |
16 | 1 | B | 0 | M | 71 | 5.45 | CON |
17 | 2 | O | 0 | F | 93 | 5.50 | CON |
18 | 2 | A | 0 | F | 85 | 4.40 | CON |
19 | 3 | C | 1 | F | 82 | 6.05 | AD |
20 | 4 | C | 2 | M | 64 | 6.00 | AD |
21 | 5 | C | 3 | F | 71 | 4.15 | AD |
22 | 6 | C | 3 | M | 65 | 8.50 | AD |
23 | 6 | C | 3 | F | 64 | 3.40 | AD |
24 | 6 | C | 3 | M | 69 | 5.30 | AD |
C. Cases used for immunohistochemistry | |||||||
Case number | Braak stage (NFT) | Phase of Aβ deposits | CERAD neuritic plaque score | Sex | Age | PMD (hrs) | Pathological diagnosis |
*25 | 0 | O | 0 | M | 74 | 8.05 | CON |
26 | 1 | O | 0 | F | 75 | 5.25 | CON |
27 | 1 | O | 0 | M | 82 | 5.50 | CON |
28 | 1 | B | 0 | F | 85 | 7.05 | CON |
29 | 1 | B | 0 | F | 73 | 7.45 | CON |
30 | 1 | O | 0 | F | 60 | 6.50 | CON |
31 | 1 | O | 0 | M | 78 | 17.40 | CON |
32 | 2 | B | 0 | F | 84 | 6.05 | CON |
33 | 2 | B | 0 | F | 83 | 4.40 | CON |
34 | 5 | C | 2 | F | 84 | 4.50 | AD |
35 | 6 | C | 3 | F | 62 | 4.45 | AD |
*36 | 6 | C | 3 | M | 60 | 6.15 | AD |
37 | 6 | C | 3 | F | 82 | 5.30 | AD |
38 | 6 | C | 3 | M | 74 | 7.40 | AD |
39 | 6 | C | 3 | F | 81 | 6.00 | AD |
40 | 6 | C | 3 | M | 73 | 6.15 | AD |
41 | 6 | C | 3 | M | 74 | 5.35 | AD |
*42 | 6 | C | 3 | F | 82 | 6.00 | AD |
*43 | 6 | C | 3 | F | 67 | 6.05 | AD |
*44 | 5/6 | NA | NA | M | 76 | 24.00 | AD, CAA type 2 |
*45 | 5 | C | 3 | M | 65 | 7.20 | AD, CAA type 2 |
46 | 6 | C | 3 | F | 87 | 8.00 | AD, CAA type 2 |